EMERGENT BIOSOLUTIONS INC. (EBS) Spending and interest coverage
- R&D / revenue · 12 months: Value 5.88%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2.45%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 5.88% | Research and development expense / revenue. Period ending 2026-06-30. $45.30M ÷ $770.20M × 100 ≈ 5.88% |
| Stock-based compensation / revenue · 12 months | 2.45% | Share-based compensation / revenue. Period ending 2026-06-30. $18.90M ÷ $770.20M × 100 ≈ 2.45% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 45.30M USD | Research and Development Expense |
| Revenue | 770.20M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 18.90M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -66.00M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $45.30M | $770.20M | $18.90M | $-66.00M | (m) | 5.88% | 2.45% | (m) | (m) |
| 2026-03-31 | $48.60M | $676.80M | $16.60M | $60.70M | (m) | 7.18% | 2.45% | (m) | (m) |
| 2025-12-31 | $53.20M | $742.90M | $16.20M | $100.10M | (m) | 7.16% | 2.18% | (m) | (m) |
| 2025-09-30 | $50.20M | $788.90M | $15.20M | $118.50M | (m) | 6.36% | 1.93% | (m) | (m) |
| 2025-06-30 | $50.50M | $851.60M | $12.70M | $106.50M | (m) | 5.93% | 1.49% | (m) | (m) |
| 2025-03-31 | $70.70M | $965.40M | $13.60M | $-98.60M | (m) | 7.32% | 1.41% | (m) | (m) |
| 2024-12-31 | $70.70M | $1.04B | $18.00M | $-108.70M | (m) | 6.77% | 1.72% | (m) | (m) |
| 2024-09-30 | $91.00M | $1.13B | $17.70M | $-143.00M | (m) | 8.09% | 1.57% | (m) | (m) |
| 2024-06-30 | $92.50M | $1.10B | $19.40M | $-449.60M | (m) | 8.39% | 1.76% | (m) | (m) |
| 2024-03-31 | $85.80M | $1.19B | $22.20M | $-539.00M | $94.30M | 7.24% | 1.87% | -5.72× | Reported |
| 2023-12-31 | $111.40M | $1.05B | $23.10M | $-726.40M | $87.90M | 10.62% | 2.20% | -8.26× | Reported |
| 2023-09-30 | $129.00M | $1.10B | $30.80M | $-737.90M | $79.00M | 11.70% | 2.79% | -9.34× | Reported |
| 2023-06-30 | $163.40M | $1.07B | $38.00M | $-548.10M | $67.80M | 15.22% | 3.54% | -8.08× | Reported |
| 2023-03-31 | $187.20M | $978.50M | $42.00M | $-327.20M | $47.00M | 19.13% | 4.29% | -6.96× | Reported |
| 2022-12-31 | $193.00M | $1.12B | $45.10M | $-172.70M | $37.30M | 17.22% | 4.02% | -4.63× | Reported |
| 2022-09-30 | $218.40M | $1.51B | $43.50M | $169.80M | $33.50M | 14.43% | 2.87% | 5.07× | Reported |
| 2022-06-30 | $228.80M | $1.60B | $42.70M | $177.10M | $33.40M | 14.28% | 2.66% | 5.30× | Reported |
| 2022-03-31 | $227.90M | $1.76B | $41.80M | $263.60M | $34.20M | 12.97% | 2.38% | 7.71× | Reported |
| 2021-12-31 | $234.00M | $1.79B | $42.40M | $352.60M | $34.50M | 13.05% | 2.37% | 10.22× | Reported |
| 2021-09-30 | $210.50M | $1.65B | $42.30M | $333.30M | $34.20M | 12.74% | 2.56% | 9.75× | Reported |
| 2021-06-30 | $245.30M | $1.71B | $41.90M | $429.30M | $33.40M | 14.36% | 2.45% | 12.85× | Reported |
| 2021-03-31 | $244.30M | $1.71B | $54.90M | $540.80M | $31.20M | 14.32% | 3.22% | 17.33× | Reported |
| 2020-12-31 | $234.50M | $1.56B | $51.00M | $433.80M | $31.30M | 15.08% | 3.28% | 13.86× | Reported |
| 2020-09-30 | $237.80M | $1.33B | $46.70M | $253.40M | $31.70M | 17.84% | 3.50% | 7.99× | Reported |
| 2020-06-30 | $206.80M | $1.26B | $42.80M | $262.90M | $34.40M | 16.42% | 3.40% | 7.64× | Reported |
| 2020-03-31 | $222.80M | $1.11B | $26.50M | $129.70M | $37.40M | 20.11% | 2.39% | 3.47× | Reported |
| 2019-12-31 | $226.20M | $1.11B | $26.70M | $114.10M | $38.40M | 20.45% | 2.41% | 2.97× | Reported |
| 2019-09-30 | $215.40M | $351.80M | $27.50M | $47.60M | $37.40M | 61.23% | 7.82% | 1.27× | Reported |
| 2019-06-30 | $199.00M | $213.70M | $26.40M | $-1.90M | $27.70M | 93.12% | 12.35% | -0.07× | Reported |
| 2019-03-31 | $159.80M | $190.60M | $22.70M | $72.10M | $19.30M | 83.84% | 11.91% | 3.74× | Reported |
| 2018-12-31 | $142.80M | $782.40M | $23.20M | $89.80M | $9.90M | 18.25% | 2.97% | 9.07× | Reported |
| 2018-09-30 | $119.30M | $705.48M | $20.07M | $131.68M | $2.74M | 16.91% | 2.85% | 48.06× | Reported |
| 2018-06-30 | $104.95M | $681.26M | $18.90M | $158.14M | $4.09M | 15.41% | 2.77% | 38.67× | Reported |
| 2018-03-31 | $105.96M | $561.83M | $18.18M | $99.89M | $4.89M | 18.86% | 3.24% | 20.44× | Reported |
| 2017-12-31 | $97.38M | $560.87M | $15.21M | $124.28M | $6.59M | 17.36% | 2.71% | 18.86× | Reported |
| 2017-09-30 | $96.00M | $518.73M | $15.76M | $122.14M | $8.27M | 18.51% | 3.04% | 14.77× | Reported |
| 2017-06-30 | $100.53M | $512.21M | $16.55M | $109.85M | $8.33M | 19.63% | 3.23% | 13.19× | Reported |
| 2017-03-31 | $102.67M | (m) | $17.56M | $99.28M | $8.03M | (m) | (m) | 12.36× | Reported |
| 2016-12-31 | $108.29M | $488.78M | $18.48M | $105.52M | $7.62M | 22.16% | 3.78% | 13.85× | Reported |
| 2016-09-30 | $141.34M | (m) | $18.57M | $74.26M | $6.68M | (m) | (m) | 11.11× | Reported |
| 2016-06-30 | $143.85M | $545.53M | $18.00M | $97.84M | $6.27M | 26.37% | 3.30% | 15.61× | Reported |
| 2016-03-31 | $149.45M | $570.16M | $17.25M | $132.91M | $6.39M | 26.21% | 3.02% | 20.81× | Reported |
| 2015-12-31 | $154.00M | $522.79M | $15.85M | $96.04M | $6.52M | 29.46% | 3.03% | 14.72× | Reported |
| 2015-09-30 | $160.48M | $502.66M | $15.18M | $90.77M | $6.10M | 31.93% | 3.02% | 14.89× | Reported |
| 2015-06-30 | $162.81M | $475.67M | $14.60M | $68.79M | $6.27M | 34.23% | 3.07% | 10.97× | Reported |
| 2015-03-31 | $159.28M | $459.89M | $13.98M | $55.20M | $6.37M | 34.63% | 3.04% | 8.67× | Reported |
| 2014-12-31 | $150.83M | $450.14M | $12.83M | $58.06M | $8.24M | 33.51% | 2.85% | 7.05× | Reported |
| 2014-09-30 | $141.86M | $400.27M | $12.23M | $36.73M | $7.05M | 35.44% | 3.06% | 5.21× | Reported |
| 2014-06-30 | $126.59M | $351.42M | $11.54M | $23.84M | $5.24M | 36.02% | 3.28% | 4.55× | Reported |
| 2014-03-31 | $119.47M | $323.53M | $10.91M | $30.69M | $3.52M | 36.93% | 3.37% | 8.71× | Reported |
| 2013-12-31 | $119.93M | $312.75M | $11.24M | $42.80M | $0.00 | 38.35% | 3.59% | (m) | Reported |
| 2013-09-30 | $125.88M | $309.24M | $11.16M | $43.54M | $20.00K | 40.71% | 3.61% | 2177.20× | Reported |
| 2013-06-30 | $124.34M | $286.73M | $11.41M | $35.21M | $14.00K | 43.36% | 3.98% | 2515.29× | Reported |
| 2013-03-31 | $124.70M | $274.68M | $11.38M | $29.16M | $14.00K | 45.40% | 4.14% | 2082.50× | Reported |
| 2012-12-31 | $120.23M | $281.89M | $11.12M | $29.97M | $6.00K | 42.65% | 3.94% | 4994.50× | Reported |
| 2012-09-30 | $113.66M | $295.23M | $11.24M | $51.92M | $0.00 | 38.50% | 3.81% | (m) | Reported |
| 2012-06-30 | $115.48M | $287.40M | $11.01M | $43.51M | $0.00 | 40.18% | 3.83% | (m) | Reported |
| 2012-03-31 | $116.32M | $305.16M | $11.01M | $55.07M | $3.00K | 38.12% | 3.61% | 18355.67× | Reported |
| 2011-12-31 | $124.83M | $273.38M | $10.74M | $32.10M | $0.00 | 45.66% | 3.93% | (m) | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $89.30M | $286.17M | $7.06M | $73.56M | $0.00 | 31.20% | 2.47% | (m) | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $74.59M | $234.79M | $5.01M | $40.15M | $7.00K | 31.77% | 2.13% | 5735.71× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |